Senators ask Gilead to explain cost of Sovaldi hepatitis drug
July 11, 2014 at 10:20 AM EDT
July 11 (Reuters) - Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough new treatment for hepatitis C, citing the expense to federal healthcare programs.